Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Jump to navigation Jump to search

WikiDoc Resources for Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Articles

Most recent articles on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Most cited articles on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Review articles on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Articles on Cytochrome P450-oxidoreductase (POR) deficiency (ORD) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Images of Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Photos of Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Podcasts & MP3s on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Videos on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Evidence Based Medicine

Cochrane Collaboration on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Bandolier on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

TRIP on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Clinical Trials

Ongoing Trials on Cytochrome P450-oxidoreductase (POR) deficiency (ORD) at Clinical Trials.gov

Trial results on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Clinical Trials on Cytochrome P450-oxidoreductase (POR) deficiency (ORD) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

NICE Guidance on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

NHS PRODIGY Guidance

FDA on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

CDC on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Books

Books on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

News

Cytochrome P450-oxidoreductase (POR) deficiency (ORD) in the news

Be alerted to news on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

News trends on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Commentary

Blogs on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Definitions

Definitions of Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Patient Resources / Community

Patient resources on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Discussion groups on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Patient Handouts on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Directions to Hospitals Treating Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Risk calculators and risk factors for Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Healthcare Provider Resources

Symptoms of Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Causes & Risk Factors for Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Diagnostic studies for Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Treatment of Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Continuing Medical Education (CME)

CME Programs on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

International

Cytochrome P450-oxidoreductase (POR) deficiency (ORD) en Espanol

Cytochrome P450-oxidoreductase (POR) deficiency (ORD) en Francais

Business

Cytochrome P450-oxidoreductase (POR) deficiency (ORD) in the Marketplace

Patents on Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Experimental / Informatics

List of terms related to Cytochrome P450-oxidoreductase (POR) deficiency (ORD)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Synonyms and keywords: ORD, POR deficiency, P450-oxidoreductase cytochrome deficiency

Overview

Cytochrome P450-oxidoreductase (POR) deficiency is a type of congenital adrenal hyperplasia that caused by mutations in the flavoprotein co-factor of the enzymes CYP17A1, CYP21A2, and CYP19A1 (aromatase). Severe Undervirilization in boys and severe virilization in girls and Antley-Bixler syndrome of craniofacial malformations are clinical finding of cytocrome P450-oxidoreductase deficiency. The mainstay of therapy for cytochrome P450-oxidoreductase deficiency is hydrocortisone to replace glucocorticoid deficiency.

Historical Perspective

In 1865, Luigi De Crecchio, an Italian pathologist was the first who discovered Congenital adrenal hyperplasia.[1]

Classification

There is no established classification system for cytochrome P450-oxidoreductase deficiency.

Pathophysiology

The cytochrome P450 oxidoreductase (POR) enzyme serves as an electron donor enzyme for many enzymes such as steroid synthesis enzymes CYP17A1, and CYP21A2. Cytochrome P450-oxidoreductase deficiency is characterized by combined CYP17A1 and CYP21A2 deficiency.

Also, cytochrome P450 oxidoreductase enzyme serves as a co-factor for an enzyme called lanosterol de-methylase (CYP51A1), which is effective in de novo cholesterol synthesis. In this disease cholesterol loss may lead to craniofacial malformations and Antley-Bixler syndrome (ABS).[2][3][4][5][6]

Causes

Cytochrome P450-oxidoreductase (POR) deficiency is caused by mutations in the flavoprotein that is a co-factor of the enzymes CYP17A1, CYP21A2, and CYP19A1 (aromatase).

Differentiating [disease name] from other Diseases

Cytochrome P450-oxidoreductase deficiency must be differentiated from other diseases that cause ambiguous genitalia such as: 21-hydroxylase deficiency, 11-β hydroxylase deficiency, 17 alpha-hydroxylase deficiency, and gestational hyperandrogenism.

Disease name Steroid status Important clinical findings
Increased Decreased
Classic type of 21-hydroxylase deficiency
11-β hydroxylase deficiency
17-α hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Gestational hyperandrogenism

Epidemiology and Demographics

Cytochrome P450-oxidoreductase (POR) deficiency is a rere disease with unknown prevalence.[7][8]

Diagnosis

Symptoms and physical Examination

Laboratory Findings

Genetic testing is the gold standard of diagnosis. Pregnenolone, progesterone and 17-hydroxyprogesterone metabolites are increased and androgen metabolites are decreased.[9]

Treatment

Medical Therapy

The mainstay of therapy for cytochrome P450-oxidoreductase deficiency is hydrocortisone to replace glucocorticoid deficiency. Gender-appropriate replacement of androgens or estrogens with progestins is necessary at the puberty time.

  • Preferred regiemen: hydrocortisone oral, 15 to 25 mg/day in 2 to 3 divided doses.

Surgery

The reconstruction surgery for ambiguous genitalia in genetically male patients may be applied.[10]

References

  1. Delle Piane L, Rinaudo PF, Miller WL (2015). "150 years of congenital adrenal hyperplasia: translation and commentary of De Crecchio's classic paper from 1865". Endocrinology. 156 (4): 1210–7. doi:10.1210/en.2014-1879. PMID 25635623.
  2. Fukami M, Nishimura G, Homma K, Nagai T, Hanaki K, Uematsu A, Ishii T, Numakura C, Sawada H, Nakacho M, Kowase T, Motomura K, Haruna H, Nakamura M, Ohishi A, Adachi M, Tajima T, Hasegawa Y, Hasegawa T, Horikawa R, Fujieda K, Ogata T (2009). "Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients". J. Clin. Endocrinol. Metab. 94 (5): 1723–31. doi:10.1210/jc.2008-2816. PMID 19258400.
  3. 3.0 3.1 Peterson RE, Imperato-McGinley J, Gautier T, Shackleton C (1985). "Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia". N. Engl. J. Med. 313 (19): 1182–91. doi:10.1056/NEJM198511073131903. PMID 2932643.
  4. 4.0 4.1 Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, Miller WL (2005). "Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis". Am. J. Hum. Genet. 76 (5): 729–49. doi:10.1086/429417. PMC 1199364. PMID 15793702.
  5. 5.0 5.1 Kelley RI, Kratz LE, Glaser RL, Netzloff ML, Wolf LM, Jabs EW (2002). "Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia". Am. J. Med. Genet. 110 (2): 95–102. doi:10.1002/ajmg.10510. PMID 12116245.
  6. 6.0 6.1 Mann RK, Beachy PA (2004). "Novel lipid modifications of secreted protein signals". Annu. Rev. Biochem. 73: 891–923. doi:10.1146/annurev.biochem.73.011303.073933. PMID 15189162.
  7. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonça BB, Fujieda K, Miller WL (2004). "Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome". Nat. Genet. 36 (3): 228–30. doi:10.1038/ng1300. PMID 14758361.
  8. Hershkovitz E, Parvari R, Wudy SA, Hartmann MF, Gomes LG, Loewental N, Miller WL (2008). "Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency". J. Clin. Endocrinol. Metab. 93 (9): 3584–8. doi:10.1210/jc.2008-0051. PMC 2567854. PMID 18559916.
  9. Shackleton C, Marcos J, Malunowicz EM, Szarras-Czapnik M, Jira P, Taylor NF, Murphy N, Crushell E, Gottschalk M, Hauffa B, Cragun DL, Hopkin RJ, Adachi M, Arlt W (2004). "Biochemical diagnosis of Antley-Bixler syndrome by steroid analysis". Am. J. Med. Genet. A. 128A (3): 223–31. doi:10.1002/ajmg.a.30104. PMID 15216541.
  10. Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.

Template:WS Template:WH